OTC Products · LP-217
Aluminium hydroxide + Magnesium hydroxide Oral suspension
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-217OTC Products
- Generic identity
- Aluminium hydroxide + Magnesium hydroxideOral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-217
- Generic ingredient
- Aluminium hydroxide + Magnesium hydroxide
- Dosage form
- Oral suspension
- Proposed strength
- Al(OH)3 320 mg + Mg(OH)2 400 mg/5 mL
- Proposed pack
- Bottle 120 mL / 200 mL
- Portfolio category
- OTC Products
About Aluminium hydroxide + Magnesium hydroxide
Aluminium hydroxide and magnesium hydroxide are antacid ingredients that neutralize gastric acid. The combination can provide symptom relief in selected acid-related complaints, but it does not identify or cure every cause of upper abdominal discomfort. An oral suspension has different handling from a tablet, and its exact composition should be checked before applying information from other antacid combinations.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical assessment distinguishes occasional symptoms from persistent reflux, ulcer disease or another diagnosis requiring investigation. Difficulty swallowing, gastrointestinal bleeding, unexplained weight loss or severe pain need medical review. Antacids may also affect the absorption of other medicines. This source specifies a two-ingredient suspension; products that also contain simeticone or other actives are different formulations and should not be treated as equivalent.
Important safety considerations
Constipation can occur with aluminium-containing antacids, while magnesium can cause diarrhoea. Kidney impairment increases concern about accumulation of these minerals. Repeated unsupervised use can obscure an underlying illness and may affect phosphate balance. Review interactions with levothyroxine, certain antibiotics and other oral medicines. A pharmacist or clinician should assess persistent symptoms, relevant comorbidity and the full medication list.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue records aluminium and magnesium hydroxide amounts per 5 mL. Confirm whether these are expressed as the hydroxides or another equivalent basis. Excipients, suspension characteristics and any measuring device require product-specific verification.
Follow the actual suspension label for mixing, measurement, storage and the period after opening. Use an appropriate measuring device rather than an ordinary household spoon. Keep the original labelled container closed and retain the leaflet for interaction and administration guidance.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review symptom duration, alarm features, kidney function and interacting medicines. Confirm the exact two-ingredient suspension and authorized patient information.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Aluminium hydroxide + Magnesium hydroxide
- Dosage form / presentation
- Oral suspension
- Catalogue strength
- Al(OH)3 320 mg + Mg(OH)2 400 mg/5 mL
- Catalogue pack
- Bottle 120 mL / 200 mL
- Portfolio category
- OTC Products
Layer 02
Unresolved product-specific fields
- The catalogue records aluminium hydroxide 320 mg plus magnesium hydroxide 400 mg per 5 mL oral suspension. It does not establish excipients, suspension vehicle, measuring device, flavour/sweetener content or whether additional active ingredients are present.
- The two bottle sizes are pack presentations only; dosing, patient eligibility and interaction-management instructions require the exact approved label.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Aluminum Hydroxide and Magnesium Hydroxidegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength, excipients and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-217, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-217.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.